MorphoSys AG Announces Election of Two New Supervisory Board Members

MUNICH, GERMANY--(Marketwire - May 31, 2012) - MorphoSys AG (FRANKFURT: MOR) (Prime Standard Segment, TecDAX) announced today that at the Company’s Annual Shareholder Meeting on Thursday, May 31, 2012, its shareholders confirmed the appointment of Ms. Karin Eastham and Dr. Marc Cluzel as new members of the Supervisory Board. Ms. Eastham and Dr. Cluzel replace Prof. Dr. Jürgen Drews and Dr. Metin Colpan. Prof. Drews has been a member of MorphoSys AG’s Supervisory Board since 1998, while Dr. Colpan joined in 2004.

“We are pleased to announce the election of two experienced new members to our Supervisory Board and look forward to working with them,” commented Dr. Gerald Möller, Chairman of the Supervisory Board of MorphoSys AG. “On behalf of the Company, I would like to thank Professor Drews and Dr. Colpan for their invaluable support in establishing MorphoSys as one of the world’s leading antibody companies.”

The shareholders of MorphoSys AG approved the following substantive management proposals put to vote at the meeting:

• Granting full discharge of the members of the Management and Supervisory Boards in respect of their activities during the business year 2011.
• The re-appointment of Dr. Gerald Möller, Dr. Daniel Camus and Dr. Geoffrey Vernon to the Company’s Supervisory Board. Following the AGM, the members of the Supervisory Board re-elected Dr. Möller as Chairman. Mr. Vernon was elected Vice Chairman.
• The appointment of PricewaterhouseCoopers AG as auditors of the Company and the MorphoSys Group for the business year 2012.
• The use of the net earnings of MorphoSys AG; Management and Supervisory Boards recommended that the net profit of the business year 2011 is carried forward as accumulated income.

At the Annual General Meeting 2012 of MorphoSys AG, 39.7% of the voting shares were represented.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The company’s AbD Serotec unit uses HuCAL and other antibody technologies to generate superior monoclonal antibodies for research and diagnostic applications.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com

HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®) and arYla(®) are registered trademarks of MorphoSys.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company’s assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

Media Release: http://hugin.info/130295/R/1616311/515446.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE [HUG#1616311]